ATE257858T1 - Cd40l mutein - Google Patents
Cd40l muteinInfo
- Publication number
- ATE257858T1 ATE257858T1 AT96921405T AT96921405T ATE257858T1 AT E257858 T1 ATE257858 T1 AT E257858T1 AT 96921405 T AT96921405 T AT 96921405T AT 96921405 T AT96921405 T AT 96921405T AT E257858 T1 ATE257858 T1 AT E257858T1
- Authority
- AT
- Austria
- Prior art keywords
- cd40l
- mutein
- cd40l mutein
- muteins
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Amplifiers (AREA)
- Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/484,624 US5962406A (en) | 1991-10-25 | 1995-06-07 | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US08/477,733 US5981724A (en) | 1991-10-25 | 1995-06-07 | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| PCT/US1996/009632 WO1996040918A2 (en) | 1995-06-07 | 1996-06-06 | Novel cd40l mutein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257858T1 true ATE257858T1 (de) | 2004-01-15 |
Family
ID=27045653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96921405T ATE257858T1 (de) | 1995-06-07 | 1996-06-06 | Cd40l mutein |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0832229B1 (de) |
| JP (1) | JP3279573B2 (de) |
| KR (1) | KR100453314B1 (de) |
| AT (1) | ATE257858T1 (de) |
| AU (1) | AU693713B2 (de) |
| CA (1) | CA2222914C (de) |
| DE (1) | DE69631331T2 (de) |
| DK (1) | DK0832229T3 (de) |
| ES (1) | ES2214541T3 (de) |
| IL (1) | IL122174A (de) |
| MX (1) | MX9709447A (de) |
| NO (1) | NO317735B1 (de) |
| NZ (1) | NZ311335A (de) |
| PT (1) | PT832229E (de) |
| WO (1) | WO1996040918A2 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| EP0961824A4 (de) * | 1996-07-10 | 2003-01-29 | Immunex Corp | Verfahren zur aktivierung von dentritischen zellen |
| DE69740107D1 (de) | 1996-12-23 | 2011-03-10 | Immunex Corp | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
| AU762574B2 (en) * | 1998-05-14 | 2003-06-26 | Immunex Corporation | Method of inhibiting osteoclast activity |
| AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| EP2295081B1 (de) | 2001-06-26 | 2018-10-31 | Amgen Inc. | Antikörper gegen OPGL |
| WO2003035887A1 (en) | 2001-09-20 | 2003-05-01 | Immunex Corporation | Selection of cells expressing heteromeric polypeptides |
| DK1594955T3 (da) | 2003-02-14 | 2012-06-25 | Biogen Idec Inc | Ekspressionskassette og vektor til transient eller stabil ekspression af eksogene molekyler |
| JP3936673B2 (ja) * | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| EP1673389A2 (de) * | 2003-10-10 | 2006-06-28 | Xencor Inc. | Varianten des cd40l-proteins |
| AU2005299716B2 (en) | 2004-10-22 | 2012-09-06 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| EP2500416A1 (de) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Verbesserungen an Zellkulturen |
| AU2007294731B2 (en) | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
| PL2066339T3 (pl) | 2006-09-18 | 2015-02-27 | Univ Arkansas | Kompozycje i sposoby zwiększania odpowiedzi immunologicznych |
| CA2691374A1 (en) | 2007-06-29 | 2009-01-08 | Asubio Pharma Co., Ltd. | Recombinant c-terminal .alpha.-amidating enzyme derivative |
| ES3006441T3 (en) | 2007-09-14 | 2025-03-18 | Amgen Inc | Homogeneous antibody populations |
| WO2009059018A1 (en) | 2007-10-30 | 2009-05-07 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
| PT3097926T (pt) | 2007-11-01 | 2020-01-08 | Univ Guelph | Composições e métodos de potenciação das respostas imunitárias frente a eimeria |
| TWI478937B (zh) | 2008-01-15 | 2015-04-01 | Abbvie Inc | 改良之哺乳動物表現載體及其用途 |
| EP3255153A1 (de) | 2009-11-17 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Verfahren für erhöhte proteinproduktion |
| ES2643646T3 (es) | 2010-01-21 | 2017-11-23 | The Board Of Trustees Of The University Of Arkansas | Vectores de vacuna y métodos para potenciar las respuestas inmunitarias |
| MX350306B (es) | 2010-06-09 | 2017-09-04 | Univ Arkansas | Vacuna y metodos para reducir una infeccion por campylobacter. |
| AR094791A1 (es) | 2013-02-14 | 2015-08-26 | Univ Arkansas | Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria |
| US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
| AU2014239557B2 (en) | 2013-03-15 | 2019-01-03 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
| UA123398C2 (uk) | 2015-08-05 | 2021-03-31 | Янссен Байотек, Інк. | Виділене антагоністичне антитіло, яке специфічно зв'язує cd154, та фармацевтична композиція, яка його містить |
| WO2017083604A1 (en) | 2015-11-12 | 2017-05-18 | Amgen Inc. | Triazine mediated pharmacokinetic enhancement of therapeutics |
| KR102767638B1 (ko) | 2016-05-03 | 2025-02-20 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법 |
| JP6972022B2 (ja) | 2016-05-11 | 2021-11-24 | アムジエン・インコーポレーテツド | グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択 |
| TW201741337A (zh) * | 2016-05-13 | 2017-12-01 | 麥迪紐有限責任公司 | ＣＤ４０Ｌ-Ｆｃ融合多肽及其使用方法 |
| US20220175781A1 (en) * | 2019-03-08 | 2022-06-09 | Obsidian Therapeutics, Inc. | Cd40l compositions and methods for tunable regulation |
| WO2026030626A1 (en) * | 2024-07-31 | 2026-02-05 | Cytonus Therapeutics, Inc. | Vaccines for cancer treatment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2198025T3 (es) * | 1991-10-25 | 2004-01-16 | Immunex Corporation | Anticuerpos contra cd40-l. |
| US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
-
1996
- 1996-06-06 IL IL12217496A patent/IL122174A/en not_active IP Right Cessation
- 1996-06-06 PT PT96921405T patent/PT832229E/pt unknown
- 1996-06-06 AT AT96921405T patent/ATE257858T1/de not_active IP Right Cessation
- 1996-06-06 DK DK96921405T patent/DK0832229T3/da active
- 1996-06-06 AU AU62638/96A patent/AU693713B2/en not_active Ceased
- 1996-06-06 MX MX9709447A patent/MX9709447A/es not_active IP Right Cessation
- 1996-06-06 ES ES96921405T patent/ES2214541T3/es not_active Expired - Lifetime
- 1996-06-06 WO PCT/US1996/009632 patent/WO1996040918A2/en not_active Ceased
- 1996-06-06 DE DE1996631331 patent/DE69631331T2/de not_active Expired - Fee Related
- 1996-06-06 JP JP50191197A patent/JP3279573B2/ja not_active Expired - Fee Related
- 1996-06-06 NZ NZ311335A patent/NZ311335A/en unknown
- 1996-06-06 CA CA002222914A patent/CA2222914C/en not_active Expired - Fee Related
- 1996-06-06 EP EP96921405A patent/EP0832229B1/de not_active Expired - Lifetime
- 1996-06-06 KR KR1019970708620A patent/KR100453314B1/ko not_active Expired - Fee Related
-
1997
- 1997-11-26 NO NO19975437A patent/NO317735B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0832229B1 (de) | 2004-01-14 |
| CA2222914A1 (en) | 1996-12-19 |
| MX9709447A (es) | 1998-02-28 |
| DE69631331T2 (de) | 2004-11-18 |
| JPH11504819A (ja) | 1999-05-11 |
| KR19990022141A (ko) | 1999-03-25 |
| CA2222914C (en) | 2002-04-02 |
| WO1996040918A3 (en) | 1997-01-23 |
| AU6263896A (en) | 1996-12-30 |
| KR100453314B1 (ko) | 2004-12-17 |
| JP3279573B2 (ja) | 2002-04-30 |
| WO1996040918A2 (en) | 1996-12-19 |
| ES2214541T3 (es) | 2004-09-16 |
| DE69631331D1 (de) | 2004-02-19 |
| PT832229E (pt) | 2004-06-30 |
| IL122174A0 (en) | 1998-04-05 |
| NZ311335A (en) | 1998-05-27 |
| IL122174A (en) | 2004-07-25 |
| AU693713B2 (en) | 1998-07-02 |
| EP0832229A2 (de) | 1998-04-01 |
| NO975437D0 (no) | 1997-11-26 |
| DK0832229T3 (da) | 2004-05-03 |
| NO975437L (no) | 1998-02-06 |
| NO317735B1 (no) | 2004-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE257858T1 (de) | Cd40l mutein | |
| DK0772624T3 (da) | Interleukin-15 | |
| ATE353906T1 (de) | Cd27 ligand | |
| DK72593D0 (da) | Rekombinant protein | |
| IS5887A (is) | Interferón-beta bræðsluprótín og notkun þeirra | |
| IL96907A0 (en) | Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application | |
| ATE259377T1 (de) | An den zelloberflächenrezeptor hek bindendes cytokin | |
| DE69737978D1 (de) | Als 2f1 bezeichnetes rezeptorprotein | |
| BR9607583B1 (pt) | plasmìdios procarióticos recombinantes. | |
| DE69818450D1 (de) | Im wesentlichen reines zonulin als physiologischer modulator von "tight junctions" bei säugern | |
| DE59410132D1 (de) | Humanes zirkulierendes cytokin cc-1 | |
| AU1435695A (en) | Recombinant human thymopoietin proteins and uses therefor | |
| SE9600742D0 (sv) | Vridbart arrangemang | |
| RU94046052A (ru) | Гены агглютинации, дрожжи | |
| BR9407357A (pt) | Novos tripeptideos utilizáveis em terapia cns e imune | |
| MX9205978A (es) | Nuevas proteinas inhibidoras de trombina de garrapatas. | |
| AU3928193A (en) | Plasmilar gene, peptide and methods of use | |
| AU6981794A (en) | Protein which catalyses peptide refolding and uses thereof | |
| WO1994021273A3 (de) | VERWENDUNG VON ANGIOGENIN UND/ODER α1-MICROGLOBULIN UND/ODER KOMPLEMENTFAKTOR D ZUR BEGRENZUNG DER SEKRETION VON PROTEINEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0832229 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |